This inventor holds 147 USPTO granted patents and 17 published patent applications, plus 2 CIPO patents and 33 EPO patents, primarily in ROR-Gamma Modulators (CPC class C07D-). Top assignees: Merck + Co., Inc., Vitae Pharmaceuticals, Inc., Boehringer Ingelheim International Gmbh. Active years: 1985-2025.
Inventors with similar research interests:
Location History:
- Norristown, PA (US) (1987)
- Audbon, PA (US) (1991 - 1992)
- North Wales, PA (US) (1992 - 1993)
- Audubon, PA (US) (1985 - 1997)
- West Point, PA (US) (1998)
- Maple Glenn, PA (US) (2014 - 2015)
- Maple Grove, PA (US) (2016)
- Maple Glen, PA (US) (1993 - 2023)
Company Filing History:
78 out of 4,770 
58 out of 85 
10 out of 1,560 
Years Active: 1985-2025
Areas of Expertise:
Title: David A Claremon: Pioneering Innovator with 145 Patents
Introduction:
David A Claremon, a highly accomplished inventor and innovator from Maple Glen, PA, has made significant contributions to the field of pharmaceuticals and biotechnology. With an impressive track record of 145 patents, his inventions have had a profound impact on the treatment of cancer, inflammatory diseases, and more. This article explores his latest patents, career highlights, collaborations, and demonstrates why David A Claremon is a name to be recognized in the world of innovations and patents.
Latest Patents:
David A Claremon's most recent patents showcase his dedication to advancing the field of medicine. In his invention titled "Inhibitors of the menin-MLL interaction," he introduces a groundbreaking approach to treat cancer and other diseases involving the menin-MLL interaction. Additionally, his patent on "Dihydropyrrolopyridine inhibitors of ROR-gamma" demonstrates his expertise in developing novel compounds for the treatment of inflammatory and autoimmune diseases. These patents symbolize his commitment to improving healthcare outcomes through cutting-edge pharmaceutical research.
Career Highlights:
During his illustrious career, David A Claremon has worked with prestigious companies such as Merck & Company, Inc. and Vitae Pharmaceuticals, Inc. At Merck, he likely played an instrumental role in developing innovative drugs and treatments that address unmet medical needs. His time at Vitae Pharmaceuticals offered him the opportunity to contribute to the discovery and development of cutting-edge pharmaceutical compounds.
Collaborations:
David A Claremon has had the privilege of collaborating with accomplished individuals in his field. Among his notable coworkers, Suresh B Singh and Colin M Tice stand out as notable contributors to the advancement of pharmaceutical and biotechnology research. Such collaborations highlight the expertise and reputation that David A Claremon has earned throughout his career.
Conclusion:
David A Claremon's impressive portfolio of 145 patents reflects his unwavering commitment to innovation in the pharmaceutical and biotechnology sectors. His work in inhibiting the menin-MLL interaction and developing novel compounds for inflammatory diseases shows his dedication to improving healthcare outcomes. Through his collaborations with esteemed professionals and his tenure at prominent companies, David A Claremon has solidified his position as a trailblazing inventor. His contributions continue to shape the landscape of innovations in medicine, leaving an indelible mark on the industry as a whole.